CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP issued a routine investor-rights notice reminding CAPR shareholders of a securities fraud class action against Capricor Therapeutics, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The complaint alleges Capricor changed the statistical analysis plan for Deramiocel clinical data without FDA agreement before resubmitting its Biologics License Application, creating a claimed risk the agency would reject the BLA for insufficient evidence of effectiveness.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.